LifeArc

Dr. Sam Barrell CBE appointed as CEO of LifeArc

Retrieved on: 
Friday, April 19, 2024
Somerset NHS Foundation Trust, NHS, LifeArc, Francis Crick, Investment, CBE, Family medicine, Assura plc, Growth, Knowledge, PACE, Patient, Medicine, Interim, Crick, Senior, Management

LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer.

Key Points: 
  • LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer.
  • Sam will join LifeArc from the Francis Crick Institute where she is currently Deputy CEO with responsibility for strategic management and operational leadership, as well as deputising for the Director, Sir Paul Nurse.
  • Sam received a CBE in 2014 for her services to healthcare.
  • On behalf of the Board of Trustees, I am delighted to welcome Sam to LifeArc.

Proposed Changes to BenevolentAI’s Board Composition

Retrieved on: 
Monday, April 15, 2024
Technology, Research, Finance, Health Technology, Professional Services, Biotechnology, Health, Science, Artificial Intelligence, Annual general meeting, CFO, Cure, Investment, AI, Neo-noir, Partnership, Business, Growth, Corporate development, GI Partners, BAI, Intellectual property, Drug discovery, LifeArc, AIM, Trust, Amphisbaena, Nomination, Therapy, Euronext Amsterdam, Abcam, P74, Research and development, Trustee, Artificial intelligence, Observation, Chairperson, Digital, Recipharm, Partner, Government, Sale, The Carlyle Group, Business development, Accel-KKR, Senior, Acquisition, F2G, Risk, Audit, AGM, Oxford Nanopore Technologies, Management

Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.

Key Points: 
  • Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.
  • Subject to their appointment at the AGM, it is proposed that Mr. Allen acts as Chair and Mr. Mulvany acts as Deputy Chair of the Board.
  • Together with the rest of the Board, they will support Chief Executive Dr. Jeorg Moeller and his team on implementing the Company’s strategy.
  • He has extensive Board experience in public and private companies and is currently Chairman of Bioventix plc, where he was appointed in 2004 and a Board Trustee of LifeArc, a leading UK medical research charity.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

Retrieved on: 
Friday, September 22, 2023
LLP, LifeArc, Cayman, Conduit, Acquisition, Patient, SAN, Offering, Transaction, Growth, Lewis Hall (soldier), Pharmaceutical industry, Cryptocurrency, Security (finance), Management, Chemistry, Pfizer

SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (Nasdaq: MURF) (“MURF”), announced today the completion of the previously announced business combination (the “Transaction”).

Key Points: 
  • SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (Nasdaq: MURF) (“MURF”), announced today the completion of the previously announced business combination (the “Transaction”).
  • Existing Conduit Pharmaceuticals shareholders will own approximately 90% of the combined company’s common stock issued and outstanding as of the closing.
  • The warrants have an exercise price of $11.50, are exercisable after 30 days after the completion of the business combination and expire five years after the completion of the Transaction.
  • The Transaction was completed on September 22, 2023
    In connection with the completion of the Transaction, MURF changed its name to Conduit Pharmaceuticals Inc.

New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced

Retrieved on: 
Friday, June 30, 2023
Pressure, Maintenance, LifeArc, Partnership, University, Therapy, Life, Doctor of Philosophy, Speech, Public, Neurodegenerative disease, University of Edinburgh, Health, Ageing, Alzheimer's Research UK, Quality of life, ML, Research, Genomics, Biomarker, Mentorship, HDR, Disorder, Dementia, Alzheimer's disease, Digital technology, HIV disease progression rates, Patient, Orangi Pilot Project, Machine learning, Algorithm, Artificial intelligence, Drug discovery, Gates Ventures, Diagnosis, AI, Neurology, Disease, Pharmaceutical industry, Industrial design, Medical device, Nursing, Eisai

- NEURii collaboration builds on Eisai's extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.

Key Points: 
  • - NEURii collaboration builds on Eisai's extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.
  • TOKYO, HATFIELD, SEATTLE, LONDON, and EDINBURGH, June 30, 2023 - (JCN Newswire) - Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement.
  • NEURii will focus its initial efforts to develop data and digital solutions to complement approved treatment options for patients and solve issues related to the prediction, prevention, management, and treatment of dementia related disorders.
  • It is envisaged that NEURii partners will explore further opportunities to scale up the program developing digital health solutions worldwide.

Groundbreaking new £100m LifeArc programme aims to improve the lives of people living with a rare disease

Retrieved on: 
Thursday, July 6, 2023
Social work, Organic, LifeArc, Partnership, Skin, ALS, MND, Quality of life, Research, Health policy, Global Health, Dementia, Genetic Alliance, Patient, Investment, Cystic fibrosis, Drug discovery, NIHR, Challenge, Diagnosis, Austria, Rare, Chronic, EB, Disease, Pharmaceutical industry

Self-funded medical research organisation and charity, LifeArc, to launch a groundbreaking Rare Disease Translational Challenge that will invest more than £100m by 2030 to improve the lives of people living with a rare disease.

Key Points: 
  • Self-funded medical research organisation and charity, LifeArc, to launch a groundbreaking Rare Disease Translational Challenge that will invest more than £100m by 2030 to improve the lives of people living with a rare disease.
  • The first commitment will be £40m for the creation of up to five Translational Rare Disease Centres across the UK that will specialise in different aspects of rare disease research.
  • The Rare Disease Translational Challenge will be a game-changer for people living with a rare disease.”
    Catriona Crombie, Head of Rare Disease Translational Challenge at Life Arc, said: “Through our Rare Disease Translational Challenge, we will leverage our expertise in drug discovery, diagnostics, and translational science.
  • In the 2023 England Rare Diseases Action Plan we highlighted our ongoing commitment to investment in rare disease research through the NIHR MRC Rare Disease Research Platform and renewed investment in the NIHR Biomedical Research Centres.

LifeArc Ventures - strong performance in 2022 & sustained investment in innovation

Retrieved on: 
Wednesday, February 1, 2023
CMO, Science, Lead, LifeArc, Antibody, Investment, Viral, System, Biotechnology, Patient, News, Atopic dermatitis, Monoclonal antibody, Risk, Death, Growth, Public, AstraZeneca, DJS, AbbVie, Association of British HealthTech Industries, Vaccine, Pharmaceutical industry, COVID-19

LONDON, Feb. 1, 2023 /PRNewswire/ -- LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, today provides an update on its portfolio.

Key Points: 
  • "We pride ourselves on the hands-on support we give our portfolio companies, offering strategic, practical and scientific guidance as well as funding.
  • We believe the award for LifeArc recognises the unique combination of skills and expertise that LifeArc and LifeArc Ventures provide to support and promote life changing science.
  • You can now follow us on our dedicated LinkedIn page and Twitter, and on our upcoming new LifeArc Ventures website.
  • We're open to new opportunities and welcome introductions, so please get in touch if you think we can help.

LifeArc Ventures - strong performance in 2022 & sustained investment in innovation

Retrieved on: 
Wednesday, February 1, 2023
CMO, Science, Lead, LifeArc, Antibody, Investment, Viral, System, Biotechnology, Patient, News, Atopic dermatitis, Monoclonal antibody, Risk, Death, Growth, Public, AstraZeneca, DJS, AbbVie, Association of British HealthTech Industries, Vaccine, Pharmaceutical industry, COVID-19

LONDON, Feb. 1, 2023 /PRNewswire/ -- LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, today provides an update on its portfolio.

Key Points: 
  • "We pride ourselves on the hands-on support we give our portfolio companies, offering strategic, practical and scientific guidance as well as funding.
  • We believe the award for LifeArc recognises the unique combination of skills and expertise that LifeArc and LifeArc Ventures provide to support and promote life changing science.
  • You can now follow us on our dedicated LinkedIn page and Twitter, and on our upcoming new LifeArc Ventures website.
  • We're open to new opportunities and welcome introductions, so please get in touch if you think we can help.

LifeArc Ventures invests in Surgery Hero, world's first digital coaching clinic for patients

Retrieved on: 
Tuesday, November 15, 2022
Growth, Technology, Length of stay, Knowledge, South Tees Hospitals NHS Foundation Trust, LifeArc, Patient, COVID-19, Association of British HealthTech Industries, CEO, Risk, Integrated care system, New Senior Investment Group, Machine learning, SFC, Dentistry, Pharmaceutical industry, Health insurance

Headquartered in London, Surgery Hero is a digital clinic that helps people prepare for and recover from surgery at home.

Key Points: 
  • Headquartered in London, Surgery Hero is a digital clinic that helps people prepare for and recover from surgery at home.
  • In addition to LifeArc Ventures, the latest round of funding welcomes new investors Crista Galli Ventures and Clarendon Fund Managers, with pre-seed investors SFC Capital following on.
  • Damien Lane (founding partner of Episode 1 Ventures) and Imran Hamid (former surgeon and Senior Investment Principal at LifeArc Ventures) both join the board.
  • "Surgery Hero has the potential to significantly improve clinical outcomes and experience for patients undergoing surgery," said Dr Imran Hamid, Senior Investment Principal at LifeArc Ventures.